Psychedelic Bulletin
Your weekly update on the psychedelics space. Connect the dots in this fast-paced ecosystem with exclusive insights, analysis, and expert comment.
Psychedelic Bulletin #137: Oregon Approves First Psilocybin Service Centre; AMA Approves Psychedelic CPT Code; MindMed Seeks to Fend Off Proxy Contest
This week: we take a look at EPIC Healing Eugene, the United States’ first licensed psilocybin service centre; the AMA approves a CPT III code for psychedelic therapy; ketamine administered under anaesthesia shows no effect on depression vs. placebo; and lots more…
Psychedelic Bulletin #136: MindMed Collaborators Share Topline LSD for MDD Results; Oregon Issues Psilocybin Licences; UK Parliament to Discuss Psilocybin Rescheduling
This week: Liechti Lab shares topline data from an LSD for MDD study; Oregon Psilocybin Services issues every class of licence, except service centres; UK parliament is set to debate psilocybin’s schedule in mid-May; and lots more…
Psychedelic Bulletin #135: A Misguided MDMA Price-Fixing Effort; Psilocybin Study’s Lukewarm Results; Dutch Government Forms MDMA Commission; Trouble at Empyrean?
This week: we look a little closer at a Mass. bill that proposes a price cap on MDMA therapy; Empyrean Neuroscience loses C-suite members; Yale psilocybin study suggests complex role of expectancy; and lots more…
Dispatch from ECNP New Frontiers: Psychedelics (Psychedelic Bulletin #134)
Our dispatch from ECNP’s 2023 New Frontiers meeting, which this year focused on Psychedelics. We recap the main themes under discussion…
Psychedelic Bulletin #133: Ketamine Clinics Close with Potential Repercussions for PAT Roll-Out; Psychedelics at SXSW; Could MDMA Be Among First Beneficiaries of Faster UK Drug Approvals?
This week: UK set to make drug approvals ‘faster and nimbler’, which could help MDMA-assisted therapy; ketamine clinics close, which could damage future PAT infrastructure; psychedelics at SXSW; and lots more…
Psychedelic Bulletin #132: COMPASS Pathways Amends Phase 3 Program; Stamets Stack Finally Patented; Learning from Zuranolone?
This week: we look at changes to COMPASS’ Phase 3 program; the Stamets Stack’s patent; and, we evaluate Zuranolone as a potential comp for psychedelic therapies. Plus lots more…